Therapeutic Area

Immune-Oncology
At Nexus BioQuest we offer a broad range of Immune Oncology services testing novel therapeutics that use the immune system to prevent, control or destroy tumours.

Recent therapeutic advances in IO include the use of check-point-inhibitors, bispecific antibodies and cellular therapeutics within the clinic. Our assays are designed to test single and combinatorial therapy using all therapeutic modalities. Assays cover key mechanisms such as ADCC, NK and CD8 cytotoxicity

Example of keys assays designed to test novel immune-oncology therapies such as check-point-inhibitors, bispecifics, ADC’s, and cellular therapies:
  • CD8 T cell: 2D/ 3D Tumour Killing Assay, Antigen-specific CTL-CEFT (phenotype, proliferation, degranulation), MART-1 specific, CTL-cytotoxicity, T cell exhaustion
  • CD4 T cell: polyclonal, MLR, antigen specificity, nTreg suppression assay, iTreg polarisation assay
  • Natural Killer Cell: activation, proliferation and killing (KIR/NKG2D/ ADCC), Cytokine Release Assay-predictive toxicity
  • Macrophage: ADCP, MDSC, M1/M2, TAM, efferocytosis, phagocytosis, Cytokine Release Assay-predictive toxicity
  • Dendritic Cell: Antigen uptake and vaccine delivery, cross presentation, neo-antigen immunogenicity; phenotyping 
  • Cancer cell: Immunogenic Cell Death, 2D/3D Tumour Killing Assays, on/off target assay, CDC
  • Fibroblast: Cancer Associated Fibroblast-multicellular tumour killing assays 
  • Epithelial Cell: on/off target assay, EMT  
  • Cellular Therapy: CAR-T (on/off target assay, cellular persistence, exhaustion, immunogenicity, tumorgenicity). NK-CAR, TCR based therapeutic, γδ T cell therapeutics (NKG2D/γδ TcR) killing
contract research organisation (CRO) for cell. Contract Assay Services

Frequently Asked Questions

  • Do you offer 3D tumour models to study immune cell mediated tumour killing? 

Yes, we provide 2D and 3D tumor models to study direct or immune-mediated tumor killing for immuno-oncology research. Our 2D and 3D models are used to test efficacy of  mono and combination therapeutics.

  • What tumour types can you work with in your assays? 

We work with a wide range of tumor types, including lung, breast, colorectal, and melanoma. Our immune-mediated tumor killing assays use real-time imaging and key inflammatory cytokines such as IFNγ to assess therapeutic effects. We have a panel of clinically relevant NucLight Red labelled tumour cell lines for screening and can include new tumour types, on request.  

  • What type of therapeutics can be tested  in your assays? 

Our assays are designed to test therapeutics that target both immune cells and tumour cells including small molecules, monoclonal antibodies, checkpoint inhibitors, cellular therapies and antibody-drug conjugates.

What Our Partners say about Nexus

Our tailored approach to assay design and execution provides precise solutions for novel therapeutics, ensuring the success of your drug development programme. Visit our testimonial page to read how our immunology CRO services and collaborative efforts have helped our partners achieve quality outcomes to their immunology-focused enquiries.

Visit our testimonial page

Drug Discovery Tool

Find the right immune assay for your therapeutic area, modality and target using our interactive Drug Discovery Tool.

Explore now
Speak to a Scientist

Learn how the Nexus BioQuest team can help with your pre-clinical drug discovery programs.

Schedule a call